First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis

BACKGROUND AND OBJECTIVE: Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐17A and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque psoriasis. METHODS: This study had two parts: single ascending...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaul, M., Jarvis, P., Rozenberg, I., Kolbinger, F., Di Padova, F., Calonder, C., Espie, P., Rondeau, J.M., Cebe, R., Huber, T., Mussmann, R., Aassi, M., Sligh, T.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246720/
https://www.ncbi.nlm.nih.gov/pubmed/33617042
http://dx.doi.org/10.1111/jdv.17071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246720/
https://www.ncbi.nlm.nih.gov/pubmed/33617042
http://dx.doi.org/10.1111/jdv.17071

Ejemplares similares